LITERATURE

1. Alfimov P.V., Kostyukova E.G., Mosolov S.M. Modern methods of overcoming therapeutic resistance in recurrent depression // Biological methods of therapy of mental disorders (evidence-based medicine - clinical practice) / Ed. S.M. Mosolov. – M.: Sotsialno-politichna dumka, pp. 438-473.
2. Biological methods of therapy of mental disorders (evidence-based medicine – clinical practice) / Ed. S.N. Mosolov. – M.: Sotsialno-politicheskaya dumka, 2012. – P. 285-286.
3. Kuchmenko D.M., Kozlovsky V.L. Pharmacodynamics of ketamine as a property of an atypical antidepressant (review) // Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. – 2013. – No. 4. – P. 20–25.
4. Kuchmenko D.M., Kozlovsky V.L. Ketamine – an atypical antidepressant or an emergency psychotropic therapy? // Review of Psychiatry and Medical Psychology named after V.M. Bekhterev. – 2014. – No. 1. – P. 3–9.

5. Mazo G.E., Neznanov N.G. Therapeutically resistant depressions. – St. Petersburg: Beresta,
6. – 448 с.
7. Mosolov S.M. Clinical application of modern antidepressants. – St. Petersburg: Medical Information Agency, 1995. – P. 21-28.
8. Mosolov S.M. Modern biological hypotheses of recurrent depression (review) // Journal of Neurology and Psychiatry named after S.S. Korsakov. – 2012. – Vol. 112, No. 11-2. – P. 29–40.

8. Aan het Rot M., Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS et al. Safety and efficacy of multiple intravenous ketamine injections for the treatment of persistent pressure DeC // Biol – 2010. – Issue 67. – Pp. 139–145.
9. Aan het Rot, Zarate CA Jr., Charney DS et al. Ketamine for depression: where should we go? // Biol Psychiatry. – 2012. – Vol. 72. – Pp. 537–547.

10. Autry E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F. et. al. NMDA receptor blockade in the resting state causes a rapid behavioral response to antidepressants // Nature. – 2011. – Issue 475. – P. 91–95.
11. Berman M., Cappiello A., Anand A., Oren D.A., Henninger G.R., Charney D.S. et al. Antidepressant effect of ketamine in patients with depression // Biol Psychiatry. – 2000. – Issue 47. – P. 351–354.
12. Beurel, Song L., Jope RS Inhibition of glycogen synthase kinase C3 is required for the rapid antidepressant effect of ketamine in mice // Mol Psychiatry. – 2011. – Issue 26. – Pp. 1068–1070.
13. Bjerre, Fontenay C. Ketamine in Melancholic Depression // Ugeskr Lager. – 2010. – Issue 172. - S. 460–461.

14. Bloch MH, Wasylink S., LanderosCWeisenberger A., ​​​​Panza KE, Billingslea E., Leckman JF et al. Effects of ketamine in the treatment of refractory obsessive-compulsive disorder // Biol – 2012. – Issue 72. – P. 964–970.
15. Carr B., Goudas LC, Denman WT, Brookoff D., Staats PS, Brennen L. et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized double-blind placebo-controlled crossover study // Pain. – 2004. – Issue 108. – Pp. 17–27.
16. Correll E., Futter G.E. Two examples of patients with major depressive disorder who received low doses (subanesthesia) of ketamine // Pain Med. – 2006. – Issue 7. – P. 92–95.

17. Denk MC, Rewerts C., Holsboer F., ErhardtCLehmann A., Turck CW Monitoring the response to ketamine treatment in a depressed patient via the peripheral target of RapamyC cin activation in mammals // Am J – 2011. – Vol. 68. – P. 751–752.
18. DeWild E., Levitch K.F., Merro J.W. et al. The promise of ketamine for treatment-resistant depression: current evidence and future directions // Ann NY Acad Sci. – 2015. – Issue 1345. – Pp. 47–58.
19. Diamond R. et al. Ketamine infusions for treatment-resistant depression: a series of patients treated weekly or twice weekly in an ECT clinic // J PsychopharmacolC ogy. – April 2014.
20. DiazGranados, Ibrahim L., Brutsche NE, Newberg A., Kronstein P., Khalife S., et al. Randomized follow-up study of the NCmethylCDCaspartate antagonist in the treatment of bipolar depression crisis // Arch Gen Psychiatry. – 2010. – Issue 67. – pp. 793–802.
21. DiazGranados N., Ibrahim LA, Brutsche NE, Ameli R., Henter ID, Luckenbaugh DA et Rapid resolution of suicidal ideation after a single infusion of the NCmethylCDCaspartate antagonist in patients with treatment-resistant major depressive disorder // J Clin PsyC chiatry. – 2010. – Issue 71. – P. 1605–1611.
22. Fond et al. al. Ketamine administration in depressive disorders: a systematic review and meta-analysis // J Psychopharmacology. – July 2014.

23. Glue, Gulati A., Le Nedelec M., Duffull S. DoseC and ExposureResponse to Ketamine in Depression // Biol Psychiatry. – 2011. – Issue 70. - S. 9–12.
24. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder with preoperative ketamine and electroconvulsive therapy // J – 2007. – Vol. 23. – P. 23–25.
25. Ibrahim, DiazGranados N., FrancoCChaves J., Brutsche N., Henter ID, Kronstein P. et al.
26. Course of improvement in depressive symptoms after a single intravenous infusion of ketamine versus AddCon Riluzole: results of a 4-week, double-blind, placebo-controlled study // Neuropsychopharmacology. – 2012. – Issue 37. – P. 1526–1533.
27. Kavalali T., Monteggia LM How ketamine induces rapid antidepressant action ReC

answer? // Curr Opin Pharmacol. – 2015. – Issue 20. – P. 35–39.

28. Kranaster L., KammererCCiernioch J., Hoyer C., Sartorius A. Clinically beneficial effects of ketamine as an anesthetic for electroconvulsive therapy: a retrospective study // Eur Arch Psychiatry Clin – 2011. – Vol. 261. – P. 575–582.
29. Krystal D, Weiner RD, Dean MD, Lindahl VH, Tramontozzi LA 3rd, Falcone G et al.

Comparison of seizure duration, ictal EEG, and cognitive effects of hexital anesthesia with ketamine and MethoC with ECT // J Neuropsychiatry Clin Neurosci. – 2003. – Issue 15. – P. 27–34.

30. Lally, Nugent A.K., Luckenbaugh D.A., et al. Neural correlates of changes in major depression

severe anhedonia disorder after ketamine OpenClabel // J Psychopharmacol. – 2015. – Issue 29. – Pp. 596–607.

31. Lee, Syeda K., Maruschak NA, et al. A new perspective on the antisuicidal effect

with ketamine treatment: precognitive effect // J Clin Psychopharmacol. – 2016. – Issue 36. – P. 50–56.

32. Loo C., Sainsbury, Martin D., MacPherson R. Synergistic antidepressant effects with

Ketamine and ECT // J ECT. – 2009. – Issue 25. – P. 150.

33. Maeng, Zarate CA Jr., Du J., Schloesser RJ, McCammon J., Chen G. et. al. Cellular mechanisms underlying the antidepressant effects of ketamine: the role of alpha-caminoC-3C-hydroxy-C5C-methylisoxazole-C4C-propionic acid receptors // Biol Psychiatry. – 2008. – Issue 63. – P. 349–352.
34. Matthew J., Merro J. W., Anhet Roth M., Collins K. A., Reich D. L., Charney D. S. Riluzole

for relapse prevention after intravenous ketamine administration in the treatment of resistant depression: a pilot randomized placebo-controlled extension study // Int J NeuropsychopharmaC col. – 2010. – Issue 13. – P. 71–82.

35. Montgomery A, Asberg M. A new depression scale designed to be sensitive to

Change // Br J Psychiatry. – 1979. – Issue 134. – P. 382–389.

36. Morgan J.A., Mützelfeldt L., Curran H.V. Effects of chronic ketamine self-administration on neurocognitive function and psychological well-being: a 1-year long-term study // Narkomania. – 2010. – Vol. 105. – Pp. 121–133.
37. Moukaddam NJ, Hirschfeld RMA Intravenous Antidepressants: A Review // Depression

Anxiety. – 2004. – Issue 19. – P. 1–9.

38. Murrough W., Collins KA, Fields J. et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder // Transl Psychiatry. – 2015. – Issue 5. – P. 509.
39. Murrough W., Gallo JM, Collins KA, Aan het Rot M., Charney DS Reply: DoseC and

Reaction to the influence of ketamine in depression // Biological Psychiatry. – 2010. – Issue 70. – Pp. 11–12.

40. Murrough JW, Perez AM, Mathew SJ, Charney DS A case of sustained remission

After an acute course of ketamine in the treatment of persistent depression // J Clin PsyC chiatry. – 2011. – Issue 72. – P. 414–415.

41. Murrough W., Perez AM, Pillemer S. et al. Rapid and long-acting antidepressant EfC

Effects of repeated ketamine infusions in the treatment of persistent major depression // Biol Psychiatry. – 2012 Jul 26.

42. Neir, Singh Ajit S. The role of the glutamatergic system in posttraumatic stress disorderC

der // CNS Spectr. – 2008. – Issue 13, No. 7. - p. 585–591.

43. Newcomer JW, Farber NB, JevtovicCTodorovic V., Selke G., Melson AK, Hershey T. et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis // – 1999. – Issue 20. – P. 106–118.
44. Okamoto, Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid AntideC

Depressant effect of ketamine anesthesia during electroconvulsive therapy of resistant depression: a comparison of ketamine and propofol anesthesia // J ECT. – 2010. – Issue 26. – P. 223–227.

45. Parides K. et al. Efficacy of intravenous ketamine for the treatment of chronic post-traumatic stress disorder

matic Stress Disorder a Randomized Clinical Trial // Jama Psychiatry. – April 2014.

46. Paul, Schaaff N., Padberg F., Moller HJ, Frodl T. Comparison of Racemic Ketamine and Sketamine in Treatment-Resistant Major Depression: Report of Two Cases // World J Biol Psychiatry. – 2009. – Issue 10. - S. 241–244.
47. Phelps, E., Brutsche, N., Moral, JR., Luckenbaugh, DA., Manji, HK., Zarate, CA. The family of Jr

History of alcohol dependence and initial antidepressant response to the aspartate antagonist NCmethylCDC // Biol Psychiatry. – 2009. – Issue 65. – pp. 181–184.

48. Pilc, Wieronska JM, Skolnick P. Glutamate-based antidepressants: preclinical psychology

pharmacology // Biol psychiatry – 2013. – Issue 73. – Pp. 1125–1132.

49. Price B., Nock M.K., Charney D.S., Matthew S.J. The effect of intravenous ketamine on overt and implicit suicidality in treatment-resistant depression // Biol Psychiatry. – 2009. – Vol. 66, No. 5. – P. 522–526.
50. Riaza BermudoSoriano, PerezCRodriguez M.M., VaqueroClorenzo C., BacaCharcia E.

New perspectives on glutamate and anxiety // Pharmacol Biochem Behav. – 2012. – Vol. 100, No. 4. – P. 752–774.

51. Rodriguez L., Kegeles L.S., Flood P., Simpson H.B. Rapid resolution of obsessive thoughts after

Intravenous ketamine infusion in a patient with treatment-resistant obsessive-compulsive disorder // J Clin Psychiatry. – 2011. – Issue 72. – P. 567–569.

52. Rodriguez CL, Kegeles LS et. al. Randomized controlled crossover trial of ketamine

in ObsessiveCcompulsive Disorder: ProofCofCconcept // Neuropsychopharmacology. – 2013. – Issue 38. - S. 2475–2483.

53. Sanacora, Kendell SF, Levin Y, Cement AA, Fenton LR, Coric V et al. Previous

Evidence of the effectiveness of riluzole in patients with residual symptoms of depression who took antidepressants // Biol Psychiatry. – 2007. – Issue 61. – Pp. 822–825.

54. Steru L., Shermat R., Thierry, Simon P. The tail suspension test: a new method for

Screening of antidepressants in mice // Psychopharmacology (Berl). – 1985. – Issue 85. – P. 367–370.

55. Trullas R., Skolnick P. Functional Antagonists at the NMDA Receptor Complex Exhibit Antidepressant Actions // Eur J Pharmacol. – 1990. – Issue 185. - S. 1–10.

56. Valentin G.V., Mason G.F., Gomez R., Fasula M., Vacl J., Pitman B. et al. The anti-depressive effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]CMRS // Psychiatry Res NeuroimagC ing. – – Issue 191. – pp. 122–127.
57. Zarate A. Jr., Singh J. B., Carlson P. J., Brutshe N. E., Amelie R., Lackenbaugh D. AND. etc.

Randomized trial of the antagonist NCmethylCDCaspartate in the treatment of persistent major depression // Arch Gen Psychiatry. – 2006. – Issue 63. – P. 856–864.

58. Zarate A. Jr., Brutsche NE, Ibrahim L. et al. Reproducing the antidepressant efficacy of ketamine in bipolar depression: the AddCon randomized controlled trial // Biol Psychiatry. – 2012.–Vol. 71, No. 11. – Pp. 939–946.
59. Zarate A. Jr., Payne J. L., Kiroz J., Sborn J., Denikoff K. K., Lackenbaugh D. etc. An

OpenClabel Trial of Riluzole in Patients with Treatment-Resistant Major Depression // Am J Psychiatry. – 2004. – Issue 161. – Pp. 171–174.

60. Zarate A. Jr., Quiroz JA, Singh JB, Denikoff KD, De Jesus G, Luckenbaum DA et al. An open-label trial of the glutamate modulator riluzole in combination with lithium for the treatment of bipolar depression // Biol Psychiatry. – 2005. – Issue 57. – P. 430–432.m for the treatment of bipolar depression // Biol Psychiatry. – 2005. – Issue 57. – P. 430–432.

Source

The Kyiv Expio Center is the first and only medical institution that provides ketamine therapy in Ukraine.